Page last updated: 2024-08-24

vorozole and Breast Cancer

vorozole has been researched along with Breast Cancer in 37 studies

Research

Studies (37)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	21 (56.76)	18.2507
2000's	10 (27.03)	29.6817
2010's	5 (13.51)	24.3611
2020's	1 (2.70)	2.80

Authors

Authors	Studies
Muftuoglu, Y; Mustata, G	1
Potter, BV; Thomas, MP	1
Airola, K; Biegon, A; Bonilla, P; Cohen, J; Dhawan, J; Franceschi, D; Pareto, D; Shroyer, KR; Tahmi, M	1
Alonso, A; Laenen, A	1
Jiao, J; Liao, Q; Xiang, H	1
A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M	1
Mokbel, K	1
Clemons, MJ; Freedman, OC; Verma, S	1
Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Milella, M; Mottolese, M; Nisticò, C; Papaldo, P; Ruggeri, EM; Terzoli, E	1
Ioannidis, JP; Mauri, D; Pavlidis, N; Polyzos, NP	1
De Coster, R; Snoeck, E; Wouters, W	1
Blankenstein, RA; de Jong, PC; Donker, TH; Maitimu-Smeele, I; Nortier, HW; Slee, PH; Thijssen, JH; van de Ven, J	1
Dowsett, M	2
Durgam, VR; Tekmal, RR	1
Amoroso, D; Boccardo, F; Brema, F; Cortesi, E; Farris, A; Guida, G; Iacobelli, S; Irtelli, L; Langenaeken, C; Mesiti, M; Mustacchi, G; Nardini, P; Pacini, P	1
Buzdar, AU; Roseman, BJ; Singletary, SE	1
Beex, LV; Houston, SJ; Klijn, J; Langenaeken, C; Nooij, M; Paridaens, R; Piccart, MJ; Roy, JA; Tomiak, E; Van Glabbeke, M; Van Vreckem, A; Vinholes, J	1
Harvey, HA	1
Beex, LV; Bonfrer, JM; Bruning, PF; Bruynseels, J; Klijn, JG; Nooij, M; Paridaens, R; Piccart, MJ	1
Huang, ML; Langenaecken, C; Piotrovsky, VK; Van Peer, A	1
Goss, PE	1
Ambus, U; Bruynseels, J; Clark, RM; Crump, M; De Coster, R; Goss, PE; Tye, LM; Wadden, NA; Walde, D; Weizel, HA	1
Bruynseels, J; De Coster, R; Goss, PE; Langenaeken, C; Walde, D	1
Hamilton, A; Piccart, M	1
Goss, PE; Schwartz, LH; Tannock, IF; Winer, EP	1
Blijham, GH; de Jong, PC	1
Coombes, RC; Doody, D; Dowsett, M; English, J; Howes, A; Miall, S	1
Bonneterre, J; Feutrie, ML	1
Harvey, HA; Santen, RJ	1
Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N	1
Kerbrat, P; Lefeuvre, C	1
Buzdar, A; Howell, A	1
Boeddinghaus, I; Dixon, M; Dowsett, M; Ebbs, S; Gui, G; Harper-Wynne, C; Hills, M; Sacks, N; Salter, J; Smith, I	1
A'Hern, R; Doody, D; Dowsett, M; Harper-Wynne, CL; Hills, MJ; Howes, A; Iqbal, J; Laidlaw, IJ; Lowe, FM; MacNeill, FA; Miall, S; Nasiri, N; Rayter, Z; Sacks, NP; Salter, J; Sauven, P; Shenton, K	1
Bijnens, L; Michiels, B; Molenberghs, G; Thijs, H; Vangeneugden, T	1

Reviews

17 review(s) available for vorozole and Breast Cancer

Article	Year
Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer. Current medicinal chemistry, 2010, Volume: 17, Issue:30 Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Chromones; Coumarins; Female; Flavonoids; Humans; Letrozole; Nitriles; Receptors, Estrogen; Sulfonamides; Triazoles	2010
The evolving role of aromatase inhibitors in breast cancer. International journal of clinical oncology, 2002, Volume: 7, Issue:5 Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Humans; Letrozole; Nitriles; Triazoles	2002
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Cancer treatment reviews, 2005, Volume: 31, Issue:1 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles	2005
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer, 2005, Oct-01, Volume: 104, Issue:7 Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Probability; Prognosis; Remission Induction; Risk Assessment; Survival Analysis; Triazoles	2005
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. Journal of the National Cancer Institute, 2006, Sep-20, Volume: 98, Issue:18 Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles	2006
Vorozole, a specific non-steroidal aromatase inhibitor. Breast cancer research and treatment, 1994, Volume: 30, Issue:1 Topics: Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Hormones; Humans; In Vitro Techniques; Male; Mammary Neoplasms, Experimental; Triazoles	1994
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. Journal of surgical oncology, 1997, Volume: 66, Issue:3 Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles	1997
Emerging role of aromatase inhibitors in the treatment of breast cancer. Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:3 Suppl 5 Topics: Aged; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Triazoles	1998
Theoretical considerations for the ideal aromatase inhibitor. Breast cancer research and treatment, 1998, Volume: 49 Suppl 1 Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles	1998
Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor. Breast cancer research and treatment, 1998, Volume: 49 Suppl 1 Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Enzyme Inhibitors; Humans; Neoplasms, Hormone-Dependent; Randomized Controlled Trials as Topic; Triazoles	1998
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:4 Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Severity of Illness Index; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles	1999
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women. The Netherlands journal of medicine, 1999, Volume: 55, Issue:2 Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Triazoles	1999
[Aromatase inhibitors]. Bulletin du cancer, 1999, Volume: 86, Issue:10 Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Estrogen Antagonists; Estrone; Female; Humans; Letrozole; Nitriles; Triazoles	1999
Use of aromatase inhibitors in breast carcinoma. Endocrine-related cancer, 1999, Volume: 6, Issue:1 Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles	1999
Steroidal aromatase inhibitors in elderly patients. Critical reviews in oncology/hematology, 2000, Volume: 33, Issue:2 Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles	2000
[Aromatase inhibitors: a review of clinical trials]. Bulletin du cancer, 2000, Volume: 87 Spec No Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles	2000
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:9 Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Fadrozole; Female; Headache; Humans; Letrozole; Nausea; Nitriles; Treatment Outcome; Triazoles; Vomiting	2001

Trials

8 trial(s) available for vorozole and Breast Cancer

Article	Year
Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer research, 1997, Jun-01, Volume: 57, Issue:11 Topics: Aged; Antineoplastic Agents; Aromatase; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Middle Aged; Triazoles	1997
Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:8 Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrone; Female; Humans; Middle Aged; Postmenopause; Triazoles	1997
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EOR Anti-cancer drugs, 1998, Volume: 9, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Hot Flashes; Humans; Middle Aged; Nausea; Tamoxifen; Triazoles	1998
Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group). Anti-cancer drugs, 1998, Volume: 9, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Hormones; Humans; Middle Aged; Postmenopause; Statistics as Topic; Treatment Outcome; Triazoles	1998
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:3 Topics: Aged; Aged, 80 and over; Aldosterone; Androgens; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Estrogens; Female; Follicle Stimulating Hormone; Humans; Hydrocortisone; Luteinizing Hormone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles	1995
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Enzyme Inhibitors; Female; Humans; Megestrol Acetate; Middle Aged; Postmenopause; Triazoles	1999
Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast cancer research and treatment, 1999, Volume: 56, Issue:1 Topics: Adult; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Goserelin; Humans; Middle Aged; Ovary; Postmenopause; Premenopause; Triazoles	1999
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Feb-15, Volume: 20, Issue:4 Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Enzyme Inhibitors; Female; Follicle Stimulating Hormone; Humans; Ki-67 Antigen; Luteinizing Hormone; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles	2002

Other Studies

12 other study(ies) available for vorozole and Breast Cancer

Article	Year
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorganic & medicinal chemistry letters, 2010, May-15, Volume: 20, Issue:10 Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Computer Simulation; Drug Design; Female; Humans; Models, Chemical; Models, Molecular; Structure-Activity Relationship	2010
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health. Journal of medicinal chemistry, 2015, Oct-08, Volume: 58, Issue:19 Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Discovery; Endometriosis; Estrone; Female; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Steryl-Sulfatase; Sulfonic Acids; Tubulin Modulators	2015
Initial Studies with Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020, Volume: 61, Issue:6 Topics: Aged; Aromatase; Breast Neoplasms; Carbon Radioisotopes; Female; Humans; Immunohistochemistry; Middle Aged; Positron-Emission Tomography; Triazoles	2020
The Functional Living Index-Cancer: estimating its reliability based on clinical trial data. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2010, Volume: 19, Issue:1 Topics: Aged; Antineoplastic Agents; Belgium; Breast Neoplasms; Discriminant Analysis; Female; Humans; Longitudinal Studies; Megestrol Acetate; Middle Aged; Patient Participation; Psychometrics; Quality of Life; Reproducibility of Results; Surveys and Questionnaires; Triazoles	2010
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. Journal of the National Cancer Institute. Monographs, 2011, Volume: 2011, Issue:43 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles	2011
Clinical development plan: (+)-vorozole. Journal of cellular biochemistry. Supplement, 1996, Volume: 26 Topics: Animals; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Enzyme Inhibitors; Estradiol; Female; Humans; Male; Neoplasms, Experimental; Rats; Research Design; Triazoles	1996
Aromatase inhibitors come of age. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:7 Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Nitriles; Triazoles	1997
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene. Cancer letters, 1997, Sep-16, Volume: 118, Issue:1 Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoglutethimide; Analysis of Variance; Anastrozole; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Enzyme Inhibitors; Fadrozole; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Ovariectomy; Postmenopause; Triazoles; Tumor Cells, Cultured	1997
Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients. Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Body Height; Body Weight; Breast Neoplasms; Female; Humans; Male; Middle Aged; Population; Regression Analysis; Sex Factors; Triazoles	1998
Rivizor--a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure. Oncology, 1999, Volume: 56, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoembryonic Antigen; Disease Progression; Enzyme Inhibitors; Estrogen Antagonists; Female; Gonadal Steroid Hormones; Humans; Middle Aged; Tamoxifen; Time Factors; Treatment Failure; Treatment Outcome; Triazoles	1999
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer research, 2001, Dec-01, Volume: 61, Issue:23 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Female; Gene Amplification; Humans; Immunohistochemistry; Ki-67 Antigen; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Triazoles	2001
Selection models and pattern-mixture models to analyse longitudinal quality of life data subject to drop-out. Statistics in medicine, 2002, Apr-30, Volume: 21, Issue:8 Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Female; Humans; Longitudinal Studies; Models, Statistical; Neoplasms, Hormone-Dependent; Patient Dropouts; Quality of Life; Triazoles	2002